Latest Industry Insights

We spoke to Dr. Audrey Dubourg, product manager at CN Bio to find out more about how its organ-on-chip platform could bridge the gap between the current 2D models and animal models, providing human-relevant insights into diseases such as non-alcoholic steatohepatitis.

Today’s treatments for AD are limited and unsatisfactory. This article explores a drug development effort that is taking a completely different approach – not trying to cure the disease but actually repair the damage.

To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.

Research is advancing exciting areas of science at an unprecedented pace, but the disposable materials, powered equipment and shipping associated with experiments, sample storage and transport of reagents contribute to high energy consumption and significant waste. How are researchers bringing sustainability to scientific discovery?

Technology Networks had the pleasure of talking to Wilfredo Marín to learn more about OPC UA and how it is suited to biobanking and cell and gene therapy development.

This article explores how automated tools are helping researchers to algorithmically “unmix” spectral ranges – producing faster, smarter and higher-quality data and providing new possibilities for interpreting image data.

To learn more about NASH “in-a-box” and how it can help to advance drug discovery for NASH, Technology Networks spoke to Dr. Audrey Dubourg.

Technology Networks had the pleasure of interviewing Sunny Himansu M.B.B.S., D.SM – associate director, infectious diseases at Moderna – to discuss the biotech company's pipeline, how a collaboration with IAVI aims to make mRNA-based preventives and therapeutics globally accessible and the future of mRNA in medicine.

Technology Networks had the pleasure of speaking with Thermo Fisher Scientific’s Don Paul Kovarcik, to learn more about the benefits and limitations of electroporation and key factors affecting electroporation performance.

For the world’s leading neuroscientists, unlocking the brain’s capacity to stimulate neural plasticity has become something of a Holy Grail. In this Insight, NervGen Pharma president and CEO Paul Brennan details why plasticity is so important for the brain.